Coherus Oncology, Inc.
CHRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $158 | $314 | $615 | $1,204 |
| - Cash | $126 | $103 | $64 | $417 |
| + Debt | $299 | $481 | $480 | $419 |
| Enterprise Value | $331 | $692 | $1,032 | $1,206 |
| Revenue | $267 | $257 | $211 | $327 |
| % Growth | 3.8% | 21.9% | -35.4% | – |
| Gross Profit | $149 | $98 | $141 | $269 |
| % Margin | 56% | 38.2% | 66.8% | 82.4% |
| EBITDA | $61 | -$194 | -$256 | -$261 |
| % Margin | 22.8% | -75.4% | -121.1% | -79.8% |
| Net Income | $29 | -$238 | -$292 | -$287 |
| % Margin | 10.7% | -92.5% | -138.2% | -87.9% |
| EPS Diluted | 0.25 | -2.53 | -3.76 | -3.81 |
| % Growth | 109.9% | 32.7% | 1.3% | – |
| Operating Cash Flow | -$20 | -$175 | -$241 | -$37 |
| Capital Expenditures | $0 | -$0 | -$2 | -$1 |
| Free Cash Flow | -$20 | -$175 | -$243 | -$39 |